Jazz Pharmaceuticals Estimates $755M Pre-Tax Acquired IPR&D Charge From Actio Biosciences Acquisition; Expected $11.00 Negative Impact On Both GAAP And Adjusted EPS In Q3 2026
Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition In connection with its acquisition of Actio Biosciences, Inc., a Delaware corporation ("Actio"), which was completed on September
Jazz Pharmaceuticals bought a company called Actio Biosciences. They expect this purchase to reduce their reported profits by about $11 per share in the third quarter of 2026.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.